Amphastar Pharmaceuticals (AMPH) Income towards Parent Company (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Income towards Parent Company of $6.4 million for Q1 2026, down 74.61% year-over-year from $25.3 million in Q1 2025, and down 86.51% quarter-over-quarter from $47.6 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Income towards Parent Company (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Income towards Parent Company history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 74.61% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $102.4 million (down 27.71% YoY), while the FY2025 annual figure was $121.2 million, down 24.26% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $6.4 million, down from $47.6 million in the prior quarter.
- The five-year high for Income towards Parent Company was $49.6 million in Q3 2023, with the low at -$145.2 million in Q4 2023.
- The 5-year median for Income towards Parent Company is $26.8 million (2023), against an average of $19.9 million.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company surged 530.36% in 2022, then sank 527.58% in 2023.
- Amphastar Pharmaceuticals' Income towards Parent Company stood at $34.0 million in 2022, then tumbled by 527.58% to -$145.2 million in 2023, then surged by 126.14% to $38.0 million in 2024, then climbed by 25.34% to $47.6 million in 2025, then tumbled by 86.51% to $6.4 million in 2026.
- Business Quant data shows AMPH's Income towards Parent Company at $6.4 million in Q1 2026, $47.6 million in Q4 2025, and $17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - |
| 10 | Amphastar Pharmaceuticals | 933.33 Mn | 643.20 Mn | 93.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.35 Mn |
| Mar 31, 2026 | 6.42 Mn |
| Dec 31, 2025 | 47.58 Mn |
| Sep 30, 2025 | 17.35 Mn |
| Jun 30, 2025 | 31.03 Mn |
| Mar 31, 2025 | 25.29 Mn |
| Dec 31, 2024 | 37.96 Mn |
| Sep 30, 2024 | 40.43 Mn |
| Jun 30, 2024 | 37.95 Mn |
| Mar 31, 2024 | 43.75 Mn |
| Dec 31, 2023 | -145.25 Mn |
| Sep 30, 2023 | 49.61 Mn |
| Jun 30, 2023 | 26.43 Mn |
| Mar 31, 2023 | 26.82 Mn |
| Dec 31, 2022 | 33.97 Mn |
| Sep 30, 2022 | 16.04 Mn |
| Jun 30, 2022 | 17.60 Mn |
| Mar 31, 2022 | 24.96 Mn |
| Dec 31, 2021 | 19.97 Mn |
| Sep 30, 2021 | 30.96 Mn |